Results 221 to 230 of about 63,989 (248)

Rivaroxaban

Reactions Weekly, 2021
  +7 more sources

Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants

Annals of Internal Medicine, 2021
BACKGROUND Gastrointestinal bleeding (GIB) rates for direct oral anticoagulants (DOACs) and warfarin have been extensively compared. However, population-based studies comparing GIB rates among different DOACs are limited.
A. Ingason, J. Hreinsson, A. S. Agustsson, S. Lund, Edward Rumba, Daníel A. Pálsson, I. E. Reynisson, Brynja R Guðmundsdóttir, P. Önundarson, E. Björnsson   +9 more
semanticscholar   +1 more source

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease

New England Journal of Medicine, 2018
Background Heart failure is associated with activation of thrombin‐related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and improve outcomes for ...
Faiez Zannad, Stefan D Anker, Mihai Gheorghiade   +2 more
exaly   +2 more sources

Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data

Annals of Internal Medicine, 2021
BACKGROUND Apixaban and rivaroxaban are replacing vitamin K antagonists for the treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons remain limited. OBJECTIVE To assess the effectiveness and safety of apixaban compared
G. Dawwas, Charles E. Leonard, J. Lewis, A. Cuker   +3 more
semanticscholar   +1 more source

Rivaroxaban

Reactions Weekly, 2023
  +4 more sources

Rivaroxaban

Reactions Weekly, 2017
  +8 more sources

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome

Annals of Internal Medicine, 2019
Antiphospholipid antibody syndrome (APS) is an acquired thrombophilic disorder in which vascular thrombosis (venous or arterial) and pregnancy losses may occur in the presence of persistent antiphospholipid antibodies (aPLs) (14).
J. Ordi‐Ros, Luis Sez-Comet, Mercedes Prez-Conesa, X. Vidal, A. Riera-Mestre, Antoni Castro-Salom, J. Cuquet-Pedragosa, V. Ortiz-Santamaria, M. Mauri-Plana, Cristina Sol, Josefina Corts-Hernndez   +10 more
semanticscholar   +1 more source

Rivaroxaban

Reactions Weekly, 2015
  +5 more sources

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial

Lancet, The, 2022
Eduardo Ramacciotti, Leandro Agati, Daniela Calderaro   +2 more
exaly  

Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study

Clinical Pharmacokinetics, 2022
Fei-Yu Zhang, Xuehai Chen, Tingting Wu, Nianxu Huang, Li Li, Dongdong Yuan, Jing Xiang, Na Wang, Wenjun Chen, Jin-hua Zhang   +9 more
semanticscholar   +1 more source